Suppr超能文献

淋巴细胞与单核细胞比值、中性粒细胞与单核细胞比值和中性粒细胞与淋巴细胞比值在新辅助化疗治疗乳腺癌患者中的预后标志物的作用。

Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.

机构信息

Breast Unit, Service of General Surgery, University Hospital Virgen de la Arrixaca, Carretera Madrid-Cartagena s/n, 30120, Murcia, Spain.

Department of Surgery, University Hospital Virgen de la Arrixaca, Murcia, Spain.

出版信息

Clin Transl Oncol. 2018 Apr;20(4):476-483. doi: 10.1007/s12094-017-1732-0. Epub 2017 Aug 7.

Abstract

BACKGROUND

Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT.

METHODS

A retrospective cohort of 150 breast cancer patients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS).

RESULTS

Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress.

CONCLUSION

High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT.

摘要

背景

如今,新辅助化疗(nCT)在乳腺癌中的应用越来越规范,不仅在晚期肿瘤中,而且在试图实现保乳手术的肿瘤中也是如此。在文献中,我们可以发现几种肿瘤类型与全身炎症反应之间的关系。我们的目的是分析在接受 nCT 治疗的乳腺癌(BC)患者的血液参数(淋巴细胞、中性粒细胞、单核细胞、淋巴细胞与单核细胞比值(LMR)、中性粒细胞与单核细胞比值(NMR)和中性粒细胞与淋巴细胞比值(NLR)的预后价值。

方法

对 150 名接受 nCT 治疗随后接受手术的乳腺癌患者进行了回顾性队列分析。收集了有关患者、组织学、化疗反应和外周血淋巴细胞、单核细胞和中性粒细胞值的数据,并用于计算 LMR、NMR 和 NLR。对变量进行单因素和多因素分析,以了解比值与无病生存(DFS)和总生存(OS)的关系。

结果

高 LMR(≥5.46)和低 NLR(<3.33)的患者复发率较低(P=0.048 和 P=0.015),尤其是 NLR 与更好的生存相关(P=0.024),这些因素预示着较好的进展。

结论

高 LMR 和低 NLR 可被视为接受 nCT 治疗的 BC 患者的有利预后因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验